BioSpace News Archive

Isofol Medical AB, reported data from the AGENT study that formed the basis for its assessment that it was not justified to continue the study.

“We are excited to announce the addition of two new target indications for batoclimab, one of which will be a pivotal program, confirming our confidence in the broad development opportunity for batoclimab,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.

Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business.

ViewRay, Inc. announced that the company’s MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration, allowing for its sale and utilization throughout China.

Nuvalent, Inc. announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR Symposium taking place October 26-28, 2022 in Barcelona, Spain.

Avivagen Inc. is pleased to announce that its scientific paper entitled “Safety and uptake of fully Oxidized Beta Carotene” has been published in the Journal of Food and Chemical Toxicology.

Arch Therapeutics, Inc. announced that it has launched a multi-site clinical study to accelerate payor adoption and differentiate the key benefits of AC5® Advanced Wound System in treating challenging wounds.

Pfizer Inc. announced that its investigational Group B Streptococcus vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.

Velocity Clinical Research, the leading integrated research site organization, announces it has acquired MedPharmics, a multi-site company based in the US.

Calyxt, Inc., a plant-based synthetic biology company, announced that Michael A. Carr, President and Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the H.C Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.